Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics

Cystic fibrosis is realizing the promise of personalized medicine. Recent advances in drug development that target the causal CFTR directly result in lung function improvement, but variability in response is demanding better prediction of outcomes to improve management decisions. The genetic modifie...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Hum Mol Genet
Glavni autori: Strug, Lisa J., Gonska, Tanja, He, Gengming, Keenan, Katherine, Ip, Wan, Boëlle, Pierre-Yves, Lin, Fan, Panjwani, Naim, Gong, Jiafen, Li, Weili, Soave, David, Xiao, Bowei, Tullis, Elizabeth, Rabin, Harvey, Parkins, Michael D., Price, April, Zuberbuhler, Peter C., Corvol, Harriet, Ratjen, Felix, Sun, Lei, Bear, Christine E., Rommens, Johanna M.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2016
Teme:
Association Studies Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5886039/
https://ncbi.nlm.nih.gov/pubmed/28171547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/hmg/ddw290
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items